Objectives: To assess the relation between Medicaid reimbursement rates and access to dental care services in the context of dentist density and dentist participation in Medicaid in each state.

Methods: Data were from Early and Periodic Screening, Diagnostic, and Treatment reports for 2014, Medicaid reimbursement rate in 2013, dentist density in 2014, and dentist participation in Medicaid in 2014. We assessed patterns of mediation or moderation.

Results: Reimbursement rates and access to dental care were directly related at the state level, but no evidence indicated that higher reimbursement rates resulted in overuse of dental services for those who had access. The relation between reimbursement rates and access to care was moderated by dentist density and dentist participation in Medicaid. We estimate that more than 1.8 million additional children would have had access to dental care if reimbursement rates were higher in states with low rates.

Conclusions: Children who access the dental care system receive care, but reimbursement may significantly affect access. States with low dentist density and low dentist participation in Medicaid may be able to improve access to dental services significantly by increasing reimbursement rates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607675PMC
http://dx.doi.org/10.2105/AJPH.2017.303962DOI Listing

Publication Analysis

Top Keywords

reimbursement rates
28
access dental
24
dental care
20
dentist density
20
dentist participation
20
participation medicaid
20
care reimbursement
12
density dentist
12
rates access
12
dentist
10

Similar Publications

Objective: Deep brain stimulation (DBS) is an effective neurosurgical option for patients with treatment-resistant obsessive-compulsive disorder (OCD). Despite being more costly than neuroablative procedures of comparable efficacy, DBS has gained popularity over the years for its reversibility and adjustability. Although the cost-effectiveness of DBS has been investigated extensively in movement disorders, few economic analyses of DBS for psychiatric disorders exist.

View Article and Find Full Text PDF

Advance Care Planning Billing Codes Associated With Decreased Healthcare Utilization in Neurological Disease.

J Healthc Manag

January 2025

Gregory Brown, MD, PhD, Department of Medicine, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania; Sol De Jesus, MD, Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania; Emily Leboffe, MD, Department of Medicine, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania; Andy Esch, MD, Center to Advance Palliative Care, New York, New York; and Kristina Newport, MD, Department of Medicine, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania.

Goals: Advance care planning (ACP) procedure codes have been established to reimburse meaningful care goal discussions; however, the utilization frequency of these codes in neurological disease is unknown. The objective of this study is to identify the association between ACP codes and healthcare utilization in chronic neurodegenerative diseases.

Methods: This is a multicenter cohort study using real-world electronic health data.

View Article and Find Full Text PDF

Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022.

Am J Manag Care

December 2024

Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306D Walker Building, Auburn University, Auburn, AL 36849-5506. Email:

Objectives: This study evaluated the uptake and costs of 3 biosimilars among Medicare and Medicaid populations for 2019 to 2022: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).

Study Design: A retrospective, descriptive study.

Methods: Using the annually aggregated, product-level utilization and cost data of biologic and biosimilar rituximab products from CMS drug spending data, total claims and costs (reimbursement and out of pocket) for all rituximab products were identified and extracted from Medicare Part B, Medicare Part D, and Medicaid.

View Article and Find Full Text PDF

The Johnson and Johnson faulty hip implant case represents one of the most significant crises in medical device history, impacting nearly 93000 patients worldwide. In response to alarming failure rates and a global recall in August 2010, countries such as Australia, the United States, and the United Kingdom quickly implemented revision surgeries and reimbursement programs to protect patient safety. In stark contrast, India's response was alarmingly delayed; defective implants continued to be sold even after the global recall.

View Article and Find Full Text PDF

Adoption of Digital Therapeutics in Europe.

Ther Clin Risk Manag

December 2024

Medical Affairs, DM&JANZ, Viatris, Amstelveen, the Netherlands.

Digital therapeutics (DTx) are an emerging medical therapy comprising evidence-based interventions that are regulatory approved for patient use, or are under development, for a variety of medical conditions, including hypertension, cancer, substance use disorders and mental disorders. DTx have significant potential to reduce the overall burden on healthcare systems and offer potential economic benefits. There is currently no specific legal regulation on DTx in the EU.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!